Robert Lechleider Sells 55,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $19.85, for a total value of $1,091,750.00. Following the transaction, the insider owned 15,805 shares in the company, valued at approximately $313,729.25. This trade represents a 77.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Up 5.4%

Shares of NASDAQ:IMNM traded up $1.08 on Monday, reaching $21.04. The company had a trading volume of 1,597,353 shares, compared to its average volume of 1,425,521. The stock has a market capitalization of $2.38 billion, a P/E ratio of -8.84 and a beta of 2.04. The stock has a 50-day moving average price of $21.13 and a 200 day moving average price of $21.72. Immunome, Inc. has a twelve month low of $7.96 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. On average, sell-side analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Pivotal bioVenture Partners Investment Advisor LLC bought a new stake in shares of Immunome in the third quarter valued at approximately $5,884,000. TD Asset Management Inc increased its position in Immunome by 15.8% during the third quarter. TD Asset Management Inc now owns 701,280 shares of the company’s stock worth $8,212,000 after acquiring an additional 95,750 shares during the period. Nan Fung Trinity HK Ltd. increased its position in Immunome by 20.7% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock worth $15,349,000 after acquiring an additional 122,450 shares during the period. SG Americas Securities LLC raised its stake in Immunome by 1,749.3% during the 4th quarter. SG Americas Securities LLC now owns 162,168 shares of the company’s stock valued at $3,483,000 after purchasing an additional 153,399 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IMNM. Stephens dropped their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Truist Financial raised their target price on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Craig Hallum lifted their target price on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Leerink Partners cut their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Finally, Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunome has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.